Back to results
US 12,344,868 B2Granted
ENPP1 polypeptides and methods of using same
AssigneeYale University
InventorsPaul Stabach, Demetrios Braddock
Life of this patent
Estimating the term…
Abstract
The present invention includes ENPP1 polypeptides with improved in vivo half-lives. The invention further provides an ENPP1 polypeptide fusion comprising an ENPP1 polypeptide fused to a Fc region of an immunoglobulin, wherein the polypeptide fusion comprises at least one point mutation.
Claims18
An ENPP1 polypeptide fusion comprising an ENPP1 polypeptide fused to a Fc region of an immunoglobulin,
- wherein the ENPP1 polypeptide comprises at least one mutation selected from the group consisting of C25N, K27T, V29N, K369N, I371T, P534N, V536T, R545T, P554L, E592N, R741D, and S766N as relating to SEQ ID NO:7.
An ENPP1 polypeptide fusion comprising an ENPP1 polypeptide and a Fc region of an immunoglobulin, wherein at least two of the following apply:
- (a) the polypeptide fusion comprises mutations M883Y, S885T, and T887E as relating to SEQ ID NO:7;
- (b) the polypeptide fusion comprises mutations P534N, V536T, M883Y, S885T, and T887E as relating to SEQ ID NO:7;
- (c) the polypeptide fusion comprises mutations E592N, H1064K, and N1065F as relating to SEQ ID NO:7.
Dependencies are inferred from the claim text.